News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Celgene International Sárl (CELG) Release: Phase III Study with REVLIMID® Continuous Therapy Demonstrates Statistically Significant Improvement in Progression-Free Survival for Patients Newly Diagnosed with Multiple Myeloma


12/13/2011 6:23:03 AM

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), announced that data from the planned interim analysis of MM-015, a phase III, randomized, double-blind study of continuous REVLIMID (lenalidomide) therapy for the treatment of patients with newly diagnosed multiple myeloma who were ineligible for stem cell transplant, reported a clinically significant improvement in progression-free survival (PFS), the primary endpoint of the study. The data, presented at the 53rd Annual Meeting of the American Society of Hematology, focused on a pre-specified sub-analysis of patients who were 75 years or younger.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES